Frédéric Amar, CEO of Esperite Group: 'Esperite has experienced turbulent headwind but is now stable again. The new perimeter of the company highlights an efficient structure, cost effective and ready to grow again. The external funding, in addition to my personal contribution, will give the necessary resources to foresee a positive development. Our goal is to become profitable and to reach our financial and commercial targets. The company continues to expand its international presence. Our unique and advanced technology puts us ahead of most of our competitors. Our new regenerative medicine organisation is ready to address new markets in addition to the historical Cord blood offer.

Esperite NV published this content on 02 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 02 October 2017 07:23:08 UTC.

Original documenthttp://www.esperite.com/?p=6371

Public permalinkhttp://www.publicnow.com/view/EB757D6671AE480282E2CE5C25C5D480471E353D